Cisplatin binding to dna
WebOct 5, 2014 · There is increasing awareness now that one important reason for cisplatin's performance is associated to the high mobility group (HMG) proteins that bind to DNA … WebMay 26, 2024 · Cisplatin is a widely used drug in the treatment of various solid tumors, such as ovarian cancer. However, while the acquired resistance significantly limits the success of therapy, some tumors, such as colorectal cancer, are intrinsically insensitive to cisplatin. Only a small amount of intracellular platinum binds to the target-genomic DNA.
Cisplatin binding to dna
Did you know?
WebCisplatin was found to bind to bovine erythrocyte-SOD at His19 with high selectivity as no other binding sites were identified. 83 Surprisingly, amine ligands as opposed to the chlorido ligand underwent ligand exchange reactions with His19 of SOD. Webwww.ncbi.nlm.nih.gov
WebFeb 28, 2024 · The advantage of this approach is that there are different structural and DNA-binding properties in comparison with cisplatin and its derivatives, which notably possesses a cis arrangement of ligands around the metal center. WebOct 15, 2010 · The mode of binding resembles the HMGB1 box A-cisplatin-DNA complex, which also lacks a primary intercalating residue. This study provides new insights into the binding mechanisms used by HMG boxes to recognize varied DNA structures and sequences as well as modulate DNA structure and DNA bending. Copyright © 2010 …
WebSynthesis, characterization, DNA binding, and cytotoxic studies of dinuclear complexes of palladium (II) and platinum (II) with 2,2-bipyridine and α,ω-diaminoalkane-N,N′-diacetic acid Nidhi Jain, R. Mittal, T. S. Srivastava, K. Satyamoorthy, M. P. Chitnis Research output: Contribution to journal › Article › peer-review 24 Citations (Scopus) WebJun 3, 2013 · Cisplatin's selectivity in killing rapidly proliferating cancer cells is largely dependent on covalent binding to DNA via cisplatin's chloride sites that had been aquated. We hypothesized that cisplatin's toxicity in slowly proliferating or terminally differentiated cells is primarily due to drug-protein interactions, instead of drug-DNA binding.
WebTransplatin, (an isomer of cisplatin that has the chlorine atoms opposite each other, rather than on the same side) also forms adducts with DNA, but mostly mono-adducts. It does …
WebIt is generally agreed that the chloride of cisplatin leaves after it enters cells, and then the Pt center together with two non-leaving amines bind to nucleic DNA to form Pt-DNA … ofpra burkina fasoWebThe cisplatin complexes bound to the purines cause unwinding of the double helix and a widening to the minor groove The 1,2-intrastrand cross-link causes a kink to the DNA molecule in the major groove Opens a hydrophobic pocket in the minor groove between the two guanine bases Raber, J. Zhu, C. Eriksson, L.A. J. Phys. Chem. ofpra englishWebThe interactions of cisplatin with other anti-cancer agents on the DNA level have been studied extensively in pre-clinical experiments. In general, combination of cisplatin with … ofpra faqWebJan 18, 2024 · Cisplatin interacts with DNA mainly in the form of Pt-d (GpG) di-adduct, which stalls cell proliferation and activates DNA … ofpra chiffres 2020WebHuman colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins These results indicate that high-level resistance of human colon cancer cells to high doses of cisplatin and oxaliplatin does not seem to be related to acquired defects in the DNA MMR proteins. ofpra éthiopieWebThus many anticancer drugs are designed to target DNA, and cisplatin is one most effective DNA-damaging agents. Its mode of action is relatively simple: The platinum atom binds to two neighboring DNA bases called guanines and cross-links them, thus widening the DNA duplex structure. my food investWebDec 19, 2024 · DNA is believed to be the critical target of the platinum-based drugs [8,9]. The structure of these drugs can be described by a general formula, cis-[PtA2X2], where A = ammonia or amine, and X = leaving group such as halide or carboxylate. In contrast to cis-Pt(II) complexes, the trans-Pt(II) derivatives have not entered a clinical trial yet. ofpra exclusion